The Additive Value of Pyridostigmine to Silodosin in Acute Urinary Retention

PHASE2CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

January 30, 2024

Study Completion Date

January 30, 2024

Conditions
Prostatic Hyperplasia
Interventions
DRUG

silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet

The participants were assigned to groups A and B. Group B received the 8 mg silodosin capsule. In contrast, Group A was administered the silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet. Over a week, each group administered their designated drug once per day

DRUG

silodosin 8 mg capsule

The participants were assigned to groups A and B. Group B received the 8 mg silodosin capsule. In contrast, Group A was administered the silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet. Over a week, each group administered their designated drug once per day

Trial Locations (1)

Unknown

Beni-Seuf University Hospital, Banī Suwayf

All Listed Sponsors
lead

Beni-Suef University

OTHER